EXOME: Biotech • Healthcare • Life Sciences

Boston
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects

1.
Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4 | National
2.
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects | Boston
3.
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Boston
4.
Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies | Boston
5.
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | San Diego
6.
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Boston

Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week

$300M

Arrowhead Pharmaceuticals, Takeda Pharmaceutical

Dewpoint Therapeutics Taps Ex-Sanofi Executive Ameet Nathwani as CEO

Invetx Appoints Bill Brondyk, Colin Giles to Executive Team

“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
Frank Vinluan | New York
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
Frank Vinluan | Europe
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
Frank Vinluan | National
Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility
Sue Sutter | Boston
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug
Frank Vinluan | National
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting
Editors | Boston
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter
Frank Vinluan | San Francisco
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Frank Vinluan | Boston
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B
Frank Vinluan | New York

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Sponsored · Whitepaper
Biotech & Early Engagement Considerations: What Companies Must Consider When Developing an Asset
Evaluating an asset for development, including the vision, development and continuum capabilities, and global versus local development
PRA Health Sciences

Sponsored · Video
The Importance of Early Planning for Biotechs & Engaging with a CRO for Molecule Development
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace

Xconomy on Demand

We offer a number of ways to subscribe for free!